Rocket Pharmaceuticals’ investigational new drug (IND) application for a Phase I clinical trial of RP-A601, an AAV.rh74-based gene therapy candidate to treat arrhythmogenic cardiomyopathy due to plakophilin 2 pathogenic variants (PKP2-ACM), has received clearance from the US Food and Drug Administration (FDA).

The dose escalation, multi-centre trial will enrol at least six adult subjects with PKP2-ACM.

Patients with implantable cardioverter defibrillators (ICDs) and who are at high risk for arrhythmias will receive 8 x 10¹³ GC/kg single dose of RP-A601 having rh74 serotype.

The study intends to assess the safety and preliminary efficacy of RP-A601 along with its impact on cardiac biomarkers and clinical predictors of ventricular arrhythmias.

Furthermore, the impact of RP-A601 on PKP2 myocardial protein expression and sudden cardiac death will be studied in the trial.

Rocket Pharma president and chief operating officer Kinnari Patel said: “RP-A601 offers the potential of a one-time, curative alternative to medical therapy, ICDs, and ablations which are associated with adverse effects, complications, and recurrence of arrhythmias and do not halt the progression of the disease.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

“Robust preclinical proof of concept has demonstrated decreased arrhythmias and increased survival.

“With IND clearance in hand, we are rapidly advancing the first investigational gene therapy for PKP2-ACM into the clinic.”

An estimated 50,000 people in the US and EU are affected with PKP2-ACM, a devastating inherited heart disease.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell...

Read more

Thank you.

You will receive an email shortly. Please check your inbox to download the Whitepaper.

By Cytiva Thematic

You have a right to withdraw your consent at any time, by clicking here. We may still continue to send you service-related and other non-promotional communications. For more information relating to our privacy practices, we invite you to review our privacy policy.